LENS trial a first of its kind large scale trial shows striking 27% reduction in diabetic retinopathy progression

Presented at the ADA Diabetes Congress 2024, the LENS TRIAL was specifically designed to investigate the effect of Fenofibrate on eye outcomes in people with early diabetic retinopathy.

Over the period of four years, this trial, involving 1,151 participants, has yielded promising results in the favor of Fenofibrate:

● 27% lower risk of progression of diabetic retinopathy

● 50% reduction in the development of macular edema

● 42% reduction in the need for treatment intervention

The benefits of fenofibrate were similar in people with both T1DM and T2DM and in people with both normal and impaired kidney function

Dr. David Preiss, Associate Professor at Oxford University & Principal investigator of LENS trial, shared his expert opinion, highlighting Fenofibrate as a valuable addition to treat people with diabetic retinopathy.